UAE (United Arab Emirates) issues new blood products law:
This article was originally published in Clinica
Executive Summary
The UAE Ministry of health last week introduced new guidelines aimed at restricting the import of blood derivatives and other biological substances. In future, such imports will have to be clearly labelled that their country of origin is free from infectious or epidemic diseases. If a company has not had the products screened in the country of origin, it must obtain a safety certificate from a laboratory approved by a member of the Gulf Co-operation Council (GCC).
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.